SOUTH SAN FRANCISCO, Calif., Dec. 3, 2015 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO), today announced that Patrick Crutcher has been appointed Head of Business Development, Chris Thorn has been appointed interim Chief Financial Officer and Edward Painter has been appointed Head of Communications and Investor Relations.
Martin Shkreli, Chief Executive Officer, said, "We are moving quickly to build a very high quality team focused on optimizing the growth opportunities at KaloBios Pharmaceuticals."
Patrick Crutcher is also a Founder and Head of Business Development for Turing Pharmaceuticals and was a key member of the business development team at Retrophin. Additionally, Mr. Crutcher was a healthcare consultant focused on private and publicly traded biotechnology companies.
Chris Thorn is also Controller of Turing Pharmaceuticals and his previous experience includes being Controller of Kamdon Corp and Audit Manager with KPMG LLP. Mr. Thorn is a certified public accountant in the State of New York.
Edward Painter is also Head of Communications and Investor Relations with Turing Pharmaceuticals. His experience includes 25 years of working with biopharma investors at numerous investment banks and managing his own investment firm. His career began with Salomon Brothers and Goldman Sachs and was most recently with UBS.
KaloBios Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing innovative therapies for diseases with unmet medical need. The Company's most advanced drug candidate is currently lenzilumab, an anti-GM-CSF mAb for chronic myelomonocytic leukemia (CMML).
For more information on KaloBios Pharmaceuticals, please visit our web site at http://www.kalobios.com.
This release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, and statements regarding the company's clinical development of lenzilumab. Forward-looking statements reflect management's current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties including, but not limited to, the company's limited cash reserves and its ability to obtain additional capital on acceptable terms, or at all, including the additional capital which will be necessary to complete the clinical trials that the company has initiated or plans to initiate; the potential timing and outcomes of clinical studies of lenzilumab undertaken now or in the future; the ability of the company to timely source adequate supply of its development products from third party manufacturers on whom the company depends; the potential, if any, for future development of any of its present or future products; the company's ability to successfully progress, partner or complete further development of its programs; the uncertainties inherent in clinical testing; the timing, cost and uncertainty of obtaining regulatory approvals; the company's ability to protect the company's intellectual property; competition; changes in the regulatory landscape or the imposition of regulations that affect the company's products; and other factors listed under "Risk Factors" in the company's most recent quarterly report on Form 10-Q filed with the Securities and Exchange Commission on August 10, 2015, the Annual Report on Form 10-K filed on March 16, 2015, and the company's other filings with the Securities and Exchange Commission.
All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. The company has no obligation, and expressly disclaims any obligation to update, revise or correct any of the forward-looking statements, whether as a result of new information, future events or otherwise.